Ikarian Capital’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-344,123
| Closed | -$11.5M | – | 190 |
|
|
2026
Q1 | $11.5M | Buy |
344,123
+275,300
| +400% | +$10.8M | 0.94% | 29 |
|
|
2025
Q4 | $3.19M | Buy |
68,823
+12,877
| +23% | +$706K | 0.25% | 81 |
|
|
2025
Q3 | $3.78M | Buy |
+55,946
| New | +$4.15M | 0.38% | 68 |
|
|
2024
Q4 | – | Sell |
-221,437
| Closed | -$11.5M | – | 203 |
|
|
2024
Q3 | $11.2M | Sell |
221,437
-224,014
| -50% | -$10.7M | 1.56% | 16 |
|
|
2024
Q2 | $18.2M | Sell |
445,451
-119,960
| -21% | -$5.08M | 3.17% | 8 |
|
|
2024
Q1 | $24.2M | Sell |
565,411
-24,832
| -4% | -$1.12M | 2.65% | 7 |
|
|
2023
Q4 | $23.8M | Buy |
590,243
+53,523
| +10% | +$1.52M | 2.22% | 11 |
|
|
2023
Q3 | $15.8M | Buy |
+536,720
| New | +$3.25M | 1.91% | 12 |
|
|
2022
Q2 | – | Sell |
-8,564
| Closed | -$29K | – | 197 |
|
|
2022
Q1 | $29K | Buy |
8,564
+451
| +6% | +$2.33K | ﹤0.01% | 189 |
|
|
2021
Q4 | $50K | Hold |
8,113
| – | – | 0.01% | 173 |
|
|
2021
Q3 | $112K | Sell |
8,113
-51
| -0.6% | -$711 | 0.01% | 206 |
|
|
2021
Q2 | $140K | Hold |
8,164
| – | – | 0.01% | 209 |
|
|
2021
Q1 | $155K | Hold |
8,164
| – | – | 0.01% | 276 |
|
|
2020
Q4 | $236K | Buy |
+8,164
| New | +$236K | 0.01% | 210 |
|
|
2020
Q3 | – | Sell |
-22,453
| Closed | -$748K | – | 207 |
|
|
2020
Q2 | $748K | Buy |
+22,453
| New | +$973K | 0.06% | 125 |
|
Ikarian Capital's SLNO Position: Q2 2026 in Review
Ikarian Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 344,123 shares — an estimated $11.5M sold.
Ikarian Capital first reported a position in SLNO in Q2 2020 and held it in 15 quarters. The position peaked at $24.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Ikarian Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Ikarian Capital sold 344,123 Soleno Therapeutics shares in Q2 2026, an estimated $11.5M.
- Ikarian Capital first reported a position in Soleno Therapeutics in Q2 2020 and held it in 15 quarters.
- Ikarian Capital's Soleno Therapeutics position peaked at $24.2M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.